Anticoagulant medications are used for treatment and prevention of (deep vein) thrombosis and embolism and also for secondary prevention of myocardial infarction and thromboembolic complications after suffering a myocardial infraction. In this work, basic properties, comparison of pros and cons and potential effect of diet on Marifarin medicine and new generation of medication: Pradaxe, Xarelta and Eliquisa, will be shown. Motivation for this work stems from the fact that Marivarin is a blood thinning medicine which reduces blood clotting by affecting the metabolism of Vitamin K. Main environmental factor that can affect the reduction or increase of effectiveness of this medication is diet. Or more specifically, any oscillations of vitamin K in the diet. Release of new medication was an attempt to circumvent the limitations of Marivarin therapy. The answer on the question if it was successful, will be given in this work based on a research that was done via an anonymous poll. Necessary condition for participation in the research was the use of one of four mentioned medicines. During statistical analysis, the participants were divided into two groups: Group M (Marifarin) and Group NOAK (Pradaxa, Xarelto and Eliquis). According to the diet research of the participants involved in the two groups, results show that Marifarin is more challenging to use. Marfarin users are more prone to avoiding Vitamin K rich food (vegetables). NOAK group is more satisfied with their therapy and less concerned with therapy risks and potential changes to their everyday activities. The price of therapy is a major factor influencing the choice, and possibly reducing life quality of the individual. Poor financial situation does not allow the individual to choose the therapy that he/she wants. Involvement of nutrition expert would allow for an increased quality in care of the users of Marfarin.